We have ongoing studies for following conditions:


Some Important Facts to Know About Alzheimer’s Disease •

Alzheimer’s disease was initially identified more than 100 years ago. However, research into its symptoms, causes, risk factors, and treatment has gained momentum only in the last 30 years. • While research has provided a lot of information about the disease, the exact cause of Alzheimer’s is still unknown. • One in nine people over the age of 65 have Alzheimer’s. For up to 5% of the more than 5 million Americans with Alzheimer’s, the onset of the disease will occur in their 40s or 50s. • In 2013, unpaid caregivers, typically immediate family members, gave an estimated 17.7 billion hours of their time to care for loved ones with Alzheimer’s. • Not only are women more likely to have Alzheimer’s, they are also more likely to be caregivers of those with Alzheimer’s.

What is the STEADFAST Study?

The STEADFAST Study is a clinical trial, or research study, that will evaluate a new investigational medication, azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild-stage Alzheimer’s disease. Azeliragon works by blocking a receptor in the brain that binds to substances such as amyloid beta, a protein thought to contribute to the symptoms of Alzheimer’s disease. There will be two groups of people in the study: • One group will receive azeliragon (5 mg daily taken orally) in addition to their regular medication(s). • One group will receive a placebo (a substance with no active ingredients) in addition to their regular medication(s). Why should I consider participating in the STEADFAST Study? • By participating in this study, you can learn more about the treatment of Alzheimer’s disease. • You may receive the study medication, azeliragon, which may be effective at slowing the progression of Alzheimer’s disease • Participating in studies helps advance research, which may help the future treatment of this currently incurable disease.

Do I qualify for this study?

You may quality for this study if you: • Have been diagnosed with mild Alzheimer’s disease. • Are at least 50 years of age. • Have been taking one or more of the following medications for at least 3 months: memantine (Namenda® or Ebixa®), galantamine (Razadyne® or Reminyl®), Aricept® or Exelon®. What will I need to do for the STEADFAST Study? • The study will last approximately 23 months and involves about 9 visits to the doctor’s office, with most visits occurring every 3 months. • You must attend all study visits with your caregiver. • You will need to take your study medication every day, as instructed. • You must continue to take your regular Alzheimer’s disease medication as you normally do. • You will need to tell the study doctor of any changes to your health or medications while in the study.

Tel: 610 277 8073



Are you one of the millions of Americans suffering from Major Depressive Disorder, or MDD?

If so, you may be eligible to participate in a research study of an investigational medication for MDD. Qualified participants must: 􀅏 􀄑􀅏􀅏be between 18 and 75 years of age, 􀄑􀅏􀅏 be currently experiencing a major depressive episode, and 􀄑􀅏􀅏 meet additional study criteria. Participants will receive all study-related care and study medication at no cost. Health insurance is not required.

To find out more and to see if you qualify for the Reset MDD Research Study, call us today at 866-KEYSTONE


Has your life been affected by bipolar depression?

If so, you may be interested in taking part in the 401 or 402 Study.

The 401 and 402 Studies are looking at a potential new treatment – an investigational medication – for bipolar depression (bipolar I or bipolar II disorder) to see whether it works, and how safe it is, for improving the symptoms of bipolar depression. The 401 Study will look at the investigational medication when it is used on its own. The 402 Study will look at the investigational medication in patients who are already taking a mood stabilizer. We are currently looking for people who experience major depressive episodes associated with bipolar disorder to take part in the 401 and 402 Studies.

You may be able to take part in the 401 or 402 Study if you:

• are between 18 and 65 years of age (inclusive) • have been diagnosed with bipolar I or bipolar II disorder • are currently having a major depressive episode that started at least 2 weeks ago, but no more than 6 months ago • have previously had at least one bipolar manic episode or mixed episode (if you have bipolar I disorder) or hypomanic episode (if you have bipolar II disorder). The studies will last up to 12 weeks and will require nine visits to the study center in Norristown, PA. If you are interested in taking part in one of these studies, or if you would like more information, please contact: Tel: 610 277 8073



If you would like to learn more about one of our studies,

please call us at 610 277 8073 or 866- KEYSTONE!